Dongkoo Bio&Pharma

Established in 1970 as Dongkoo Pharmaceutical by the late founder Cho Dong-sub, Dongkoo Bio&Pharma has evolved from a specialized pharmaceutical firm into a comprehensive healthcare company. The current Chairman and CEO, Cho Yong-joon, son of the founder, took the helm in 2005 and has since driven the company's significant growth and diversification. The company rebranded to Dongkoo Bio&Pharma in 2014, signaling its expansion into the biotechnology sector. A major milestone was achieved in 2013 when the company became the number one prescription provider in the South Korean dermatology market, a position it continues to hold.

Dongkoo Bio&Pharma's business is structured around several key pillars. The core of its operation is the manufacture and sale of prescription drugs, with a strong focus on dermatology and urology, and an expanding presence in internal medicine and otolaryngology. This is complemented by a high-growth contract development and manufacturing organization (CDMO) business, which leverages the company's advanced manufacturing facilities, particularly its expertise in soft capsule technology. The firm generates revenue through the sale of its own pharmaceutical products and by providing manufacturing and development services to other pharmaceutical companies.

The company has significantly expanded its scope beyond traditional pharmaceuticals. In 2015, it launched SmartX®, the world's first stem cell extraction kit, marking a significant entry into the bio-industry. This was followed by the launch of 'Cell Bloom' in 2016, a cosmeceutical brand that combines stem cell-based ingredients with natural extracts. The product portfolio includes a wide range of prescription medicines, medical devices like the SmartX kit, and the Cell Bloom skincare line, which features creams and masks aimed at skin rejuvenation and anti-aging. The company also engages in strategic venture investments to secure future growth engines and is actively expanding its global footprint, with recent joint ventures and subsidiary establishments in Southeast Asia and Mongolia.

Keywords: pharmaceutical manufacturing, dermatology, urology, contract development and manufacturing organization, CDMO, cosmeceuticals, stem cell technology, prescription drugs, healthcare company, specialty pharmaceuticals, Cell Bloom, SmartX kit, generic drugs, drug formulation, Korean pharmaceutical, bio-industry, pharmaceutical exports, clinical development, drug research, pharmaceutical investment